I gennemsnit bevaredes den positive behandlingseffekt i 102 uger med vedvarende opretholdelse af synsskarpheden hos patienter randomiseret igen til at fortsætte med pegabtanip.
On average, the treatment benefit was maintained at 102 weeks with continuing preservation of visual acuity for patients re-randomized to continue pegaptanib.